Investing.com - Cerevel Therapeutics Holdings reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations.
Cerevel Therapeutics Holdings announced earnings per share of $-0.66 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.62 on revenue of $0.00.
Cerevel Therapeutics Holdings shares are down 27% from the beginning of the year, still down 45.47% from its 52 week high of $46.16 set on November 8, 2021.
Cerevel Therapeutics Holdings shares lost 7.16% in intra-day trade following the report.
Cerevel Therapeutics Holdings follows other major Healthcare sector earnings this month
Cerevel Therapeutics Holdings's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar